Member Info for crumbs

Funny how they are all new arrivals too lol ..... games!

I suppose the strangest thing is missing iSCIB2 ....

Yes you probably should and whilst there get some business cards to send to the IDS board who seem willing to sink the company all because they have a personal issue with CWU leadership and can't take social media criticism and being exposed.... Meanwhile, still the mail piles up and up and up and who is going to deliver it? Agency? nah they don't like the rain and have their social lives to organise on their phones .... so who the managers? hahahah they are the champions of hide and seek...how about the greatest asset the company has the posties who know their areas and customers better than anyone...

Many are shareholders

The 'intend' to partner does not look like 'seek out a partner to me so if proof of concept is indeed proven it seems likely there already is a partner possibly even a few have lined themselves up under CDAs

Maybe now Lindy will do the proactive vid

It is post-period so we won't get to know yet.... let's just go with the 1% so possibly $2 million with current cash burn could do with more deal/s though a milestone to $204 million would cover everything for a decent amount of time

The clowns on here who constantly **** the posties have abso-effing-lutely no idea of the huge mismanagement of this company from top to bottom the business runs on overtime so good luck in cutting that and still having a service... not that they care about mail but at some point, it will be piled in the streets and then it will become political the current BOD are killing the business now is that incompetence or something worse as in deliberate

;The Company's current GlyMab® technology generates highly selective murine mAbs, which are subsequently humanised. This platform is now being complemented by a new discovery research technology that enables us to produce fully-human mAbs directly from human blood. Scancell will use both of these methods to further generate, characterise and develop novel anti-glycan mAbs. Furthermore, the Company is applying its AvidiMab® modifications to commercially available mAbs to improve their therapeutic indices and efficacy profiles.;

nice

'In June 2022, the Company announced that the first patient had been dosed in Cohort 1 of ModiFY and all three patients in the cohort have now received two doses. The injections were well tolerated with no safety concerns. Three patients have been recruited to Cohort 2 and are currently receiving higher doses of the two citrullinated vimentin peptides plus a citrullinated enolase peptide. The Company expects safety and immunogenicity data to be available later this year and early efficacy data in 2023.'

'Genmab made an upfront payment to Scancell '
So money has come in..... interesting that AvidiMab is being used with none scancell Mabs to explore its potential

I think we are on the radar in as much as the Pfizer vax is really the BioNtech vax and they certainly know about Covidity as there is a relationship there and it was even presented at their conference ....I don't subscribe to any conspiracy theories of tech being bought to be suppressed it's much more likely to be taken on by a pharma who is yet to enter the Covid vax race... a kind of leapfrog deal for say Roche/Merck etc... if the data is compelling that is

'Have I missed anything ?'

The Scancell surprise! We know they like to do those from time to time lol

Another potential is a partnership on everything a kinda Genentech set up where Roche took a major stake and eventually bought them out, though again not sure Lindy would accept that on moditope

Baby has to walk first :) and I think Lindy as far as moditope is concerned wants it to talk too before deal/s are done

ImmunoBody is a different matter and we know Covidity will not progress without a partner and possibly that partner if there is one would want to take on the whole platform or indeed possibly fully buy that platform if the data is coming in compulsive... It's doubtful someone would swoop in with an acceptable buyout for the entire pipeline at this time and like I say no way to my mind will Lindy sell moditope at this stage....Of course, Lindy not doing a proactive on the MaB RNS could simply be she is too busy or ill or some such... though she has done media quotes so hmm

Ok, the speculation of scancell being about to be bought out is nothing new.... That has been speculated from the beginning of its listing but as others have stated that is not likely in fact lit is ess likely to happen than ever before now because we have 3 trials in progress and are bringing money in from Glycan MaB deals (the plan)....I do get how people especially newbies can read the leaves into seemingly it's obvious this is about to be taken out ....However, the fact is this is Lindy's baby and she knows its potential worth no way is especially moditope ever being given away... it's too soon we have data coming we have more deals to be done... What I will say is I agree with the mystery of no Lindy proactive or another interview on the MaB deal news seeing as this is game-changer news so yes I'm in the camp of there must be something else coming.... Remember we don't need to sell but for instance, Covidity needs a partner and will not progress without one so what I'd suspect is other big news which could possibly be a partnership of some kind....

The of scancell interest bit:

268 Multiple studies have reported the detection of Nucleocapsid (N)-specific humoral and cellular responses in most
269 COVID-19 patients (Grifoni et al., 2020, Long et al., 2020, Okba et al., 2020), suggesting that N glycoprotein could
270 be an alternative target for next-generation COVID-19 vaccines. Rice et al. generated a bivalent human adenovirus
271 serotype 5 (hAd5) vaccine, comprising of sequence for both S and N proteins, generated enhanced de novo antigen272 specific humoral and cellular responses in antigen-naïve preclinical models (Rice et al., 2020). Similarly, Brentville
273 et al. generated a DNA vaccine encoding both the RBD of S and N glycoproteins, elicited strong humoral response
274 coupled with proinflammatory CD4 Th1 and CD8 T cell responses, which provided effective cross-protection against
275 the Alpha, Beta and Delta variants (Brentville et al., 2021).
276 The emergence of the Omicron variant is a wake-up call for us that new-generation vaccines are needed to fight against
277 COVID-19 pandemic. Current available data with SARS-COV-2 and past experience with SARS-CoV and MERS278 CoV human infections would suggest that vaccines that target the more conserved N glycoproteins by inducing both
279 humoral and cellular immunity could be an effective way to overcome the viral immune escape due to mutations in
280 the S glycoprotein.

https://www.cell.com/iscience/pdf/S2589-0042(22)01651-0.pdf?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2589004222016510%3Fshowall%3Dtrue

I think it is a testament to Lindy that she keeps such good relationships to those who she has mentored such as the bright talent that is Jiaxin

$4.15 million upfront I meant not $4.15 that is crakin territory aghh ... coffee time

GenMab Synaffix deal in January of this year $415 million in milestones plus single digits royalties on commercial.... $4.15 upfront.... so yeah not 10% I'm afraid lol

still, they do different deals so this is just an example though maybe realistic for us

I got that wrong 1% !!

His dreams are our nightmares though! lol and yes I didn't realise that the relationship went back so far... I do know there is a relationship research-wise with SeaGen going back years too....

Also been looking at upfronts and GenMab deals.... one they do is 10% of milestones so in scancells case that would be $2.08 million upfront for each product they decide to pursue...might be realistic that